Home › Blog › Weight Loss › Ozempic vs Mounjaro UK

Ozempic vs Mounjaro UK 2026: The Complete Comparison — And the Crucial Distinction You Need to Know

The Critical Distinction: Ozempic Is NOT a Weight Loss Medication

The single biggest source of confusion in UK weight loss medication is the relationship between Ozempic and Wegovy. Here is the complete clinical picture:

Ozempic and Wegovy contain the same active ingredient — semaglutide — but at different doses and with different licensed indications. Wegovy is the higher-dose, weight-management-licensed version. Prescribing Ozempic off-label for weight loss (which some providers do) is technically possible but uses a diabetes medication outside its licensed indication — meaning it lacks the formal weight management dose escalation protocol and the NICE-approved efficacy and safety profile of Wegovy.

Why Are So Many People Searching “Ozempic” for Weight Loss?

Ozempic became a cultural phenomenon before Wegovy was widely available in the UK. During the period when Wegovy supply was severely constrained (2022–2023), GPs and private providers began prescribing Ozempic off-label for weight loss — producing results and generating social media content under the Ozempic name. By the time Wegovy became reliably available, the public had absorbed “Ozempic” as the generic term for semaglutide weight loss — even though Ozempic remains technically licensed only for type 2 diabetes.

The result is a significant public confusion: millions of people searching “Ozempic” who mean “Wegovy.” This guide addresses that confusion directly and then provides the complete Wegovy vs Mounjaro comparison that is clinically relevant for weight management patients.

Ozempic vs Wegovy: How Are They Different?

The Real Comparison: Wegovy vs Mounjaro for Weight Loss

For patients interested in weight management — which is what “Ozempic vs Mounjaro” searches usually mean — the clinically relevant comparison is Wegovy vs Mounjaro. Here is the complete head-to-head, including the landmark SURMOUNT-5 trial that compared them directly.

SURMOUNT-5: The head-to-head trial

Published in the New England Journal of Medicine in 2025, SURMOUNT-5 was the first randomised trial to directly compare tirzepatide (Mounjaro) with semaglutide (Wegovy) at equivalent maximum doses in adults with obesity without type 2 diabetes. Results:

Full Wegovy vs Mounjaro Comparison: Every Factor

Ozempic for Weight Loss: The Supply Context

One question Slinic receives frequently is whether patients can get Ozempic prescribed for weight loss as a cheaper alternative to Wegovy. The clinical answer is no — and here is why:

• Off-label prescribing carries additional risk — prescribing Ozempic for weight loss uses a medication outside its licensed indication, removing the formal clinical and regulatory framework that governs the weight management use of semaglutide
• The doses are different — Ozempic’s maximum dose for diabetes is 2mg. Wegovy’s standard maintenance dose is 2.4mg, and the 7.2mg step-up dose (MHRA approved January 2026) produces 20.7% average weight loss. Off-label Ozempic for weight loss cannot reach the higher efficacy doses that Wegovy enables.
• Supply cannibalisation — NHS England and the MHRA have both raised concerns that off-label Ozempic prescribing for weight loss creates supply problems for T2D patients who depend on Ozempic clinically. Slinic’s policy is to never prescribe off-label when a licensed alternative exists.
• The correct licensed product is available — Wegovy is now reliably available in the UK at Slinic. There is no clinical justification for using Ozempic off-label for weight management when the properly licensed weight management medication is accessible.

Who Should Choose Mounjaro vs Wegovy: A Clinical Decision Guide

What About Ozempic Availability in the UK?

Ozempic is available in the UK on NHS prescription for type 2 diabetes patients. It is not prescribed by Slinic for weight loss (off-label). If you have type 2 diabetes, your GP can prescribe Ozempic under NHS diabetes management pathways — or under the April 2026 QOF incentive programme for tirzepatide. If you want weight management using semaglutide, Wegovy is the correct licensed product and is available at Slinic from £99.99/pen.

The Semaglutide Family: Complete Overview

Tirzepatide (Mounjaro) vs Semaglutide (Wegovy): The Mechanism Difference

The clinical reason Mounjaro produces greater weight loss than Wegovy is its dual mechanism:

Wegovy (semaglutide) — GLP-1 agonism only

Semaglutide activates GLP-1 receptors — stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and activating appetite-suppressing pathways in the hypothalamus. This is the original GLP-1 mechanism that has been developed since liraglutide (Saxenda/Victoza) in the 2010s.

Mounjaro (tirzepatide) — GLP-1 AND GIP dual agonism

Tirzepatide activates both GLP-1 and GIP receptors simultaneously. GIP (glucose-dependent insulinotropic polypeptide) is a second incretin hormone that has complementary effects on insulin secretion, fat metabolism, and — controversially — may partially counterbalance GLP-1’s GI side effects. The dual mechanism produces greater appetite suppression and metabolic effects than GLP-1 agonism alone, which explains the superior weight loss results.

Switching Between Ozempic, Wegovy and Mounjaro

For patients on Ozempic (prescribed off-label for weight loss by a previous provider) who want to transfer to a properly licensed weight loss medication at Slinic, here is the clinical process:

The NHS Position on Ozempic for Weight Loss

NHS England has been explicit about the prescribing of GLP-1 medications for weight loss. The approved NHS pathways are:

• Wegovy (semaglutide) — licensed for weight management via NICE TA875 (BMI 35+ with one condition, via tier 3 services) and NICE cardiovascular guidance April 2026 (BMI 27+ with established CVD, via GP)
• Mounjaro (tirzepatide) — licensed for weight management via NICE TA1026 (BMI 35+ with four conditions from June 2026, via tier 3 or QOF GP pathway)
• Ozempic (semaglutide) — NOT approved for NHS weight management. Its NHS licence is for type 2 diabetes only.

NHS England has specifically warned against off-label prescribing of Ozempic for weight loss, partly due to concerns about supply disruption for T2D patients and partly because the licensed weight management alternatives — Wegovy and Mounjaro — are available and appropriate.

Social Media and the Ozempic Narrative

Understanding how Ozempic became a cultural phenomenon is important context for the Ozempic vs Mounjaro comparison. Several factors drove the confusion:

Timeline of events

• 2021: Wegovy approved by FDA in the US and clinical results go viral on social media — patients share before-and-after content under the “Ozempic” label (conflating the two semaglutide products)
• 2022: Ozempic and Wegovy supply shortages hit globally. Some UK providers prescribe Ozempic off-label for weight loss as Wegovy is unavailable. Social media content under “Ozempic” proliferates.
• 2023: Mounjaro approved for obesity in UK. “Ozempic vs Mounjaro” becomes a high-volume search term — even though the clinically correct comparison is Wegovy vs Mounjaro.
• 2024–2025: Wegovy supply stabilises. Ozempic remains the public-facing term for semaglutide weight loss despite Wegovy being the correct product. Mounjaro becomes dominant in private weight loss market (4 in 5 patients, UCL 2026).
• January 2026: MHRA approves Wegovy 7.2mg — higher dose narrowing the efficacy gap with Mounjaro to ~1.8 percentage points.
• June 2026: MHRA approves Wegovy pill (oral semaglutide 25mg) — first daily oral weight loss tablet, removing the injection requirement for Wegovy.

Cost Comparison: Ozempic vs Wegovy vs Mounjaro

For patients weighing up costs, here is the complete comparison — noting that Ozempic off-label for weight loss should not be the first choice when licensed alternatives are available.

What Happens if You Switch From Ozempic to Mounjaro or Wegovy

Patients who have been taking Ozempic off-label for weight loss and want to transfer to a properly licensed product frequently ask about the clinical transition. Here is the framework:

Transferring from Ozempic to Wegovy

Since both contain semaglutide, transfer is straightforward. Stop Ozempic on your usual injection day. Begin Wegovy 0.25mg the following week. Escalate as per the standard Wegovy protocol (0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg → 7.2mg if needed). No washout period is required. Your clinical experience on semaglutide continues — you are simply switching to the correctly licensed product at the appropriate dose escalation pathway.

Transferring from Ozempic to Mounjaro

Tirzepatide and semaglutide are different drugs. Stop Ozempic on your usual injection day. Allow one week, then begin Mounjaro 2.5mg. You must start at the Mounjaro initiation dose regardless of how long you have been on semaglutide — the receptor activation pathways are different and your tolerance for tirzepatide is not established by previous semaglutide exposure. Escalate as per the standard Mounjaro protocol.

Patient Scenarios: Which Is Right for You?

The Bottom Line: Ozempic vs Mounjaro for Weight Loss

Here is the clinical bottom line, clearly stated:

• Ozempic is not licensed for weight loss in the UK — Wegovy is the correct licensed weight management product containing semaglutide
• Mounjaro produces approximately 22.5% average weight loss at maximum dose versus 14.9–20.7% for Wegovy — a meaningful difference for patients seeking maximum results
• Wegovy has a formal NICE cardiovascular benefit label (April 2026) that Mounjaro does not yet have — making it the preferred choice for patients with established CVD
• Wegovy is cheaper (£99.99–£209.99 vs £139–£285 at Slinic) — important for cost-sensitive patients
• Wegovy now has a pill option (MHRA June 2026) — important for needle-phobic patients
• Mounjaro is the right choice for patients who want maximum weight loss and can afford it
• Neither Ozempic off-label nor any unregistered product should be your first choice when licensed alternatives are available from a GPhC-regulated UK pharmacy

Side Effects: Ozempic vs Wegovy vs Mounjaro

Since Ozempic and Wegovy contain the same drug, their side effect profiles are qualitatively identical — the differences are quantitative (higher Wegovy doses produce more side effects than lower Ozempic doses). Mounjaro has a different drug class with a partially different side effect profile.

The key clinical observation: at comparable doses (2mg Ozempic vs 2.4mg Wegovy), Wegovy’s side effect rates are higher because 2.4mg is pharmacologically more active than 2mg. Mounjaro’s nausea rates are lower than Wegovy 2.4mg despite producing greater weight loss — likely due to the GIP mechanism partially counterbalancing GLP-1’s GI effects. Wegovy 7.2mg produces the unique dysaesthesia side effect (22.9%) not seen with Mounjaro or standard Wegovy doses. For a complete side effect guide, see our weight loss injection side effects comparison.

What the SURMOUNT-5 Trial Means for UK Patients

The publication of SURMOUNT-5 in the NEJM in 2025 was a landmark moment — the first time tirzepatide and semaglutide were directly compared in a randomised controlled trial for weight management. Before this trial, the comparison between Mounjaro and Wegovy relied on cross-trial comparisons (comparing SURMOUNT-1 results with STEP 1 results), which is methodologically weaker than a head-to-head trial. SURMOUNT-5 resolved the question definitively.

Key SURMOUNT-5 findings UK patients should know

• Mounjaro produced 20.2% average weight loss vs Wegovy’s 13.7% — in the same trial, at the same time, with the same population
• Nearly twice as many Mounjaro patients achieved 20%+ weight loss (31.6% vs 16.1%)
• Three times as many Mounjaro patients achieved 25%+ weight loss (15.4% vs 5.0%) — indicating Mounjaro’s advantage is more pronounced at higher levels of weight loss
• Tolerability was comparable — discontinuation rates due to adverse events were similar between the two medications

The practical implication is clear: for patients where maximum weight loss is the primary goal and cost is not a barrier, SURMOUNT-5 provides strong evidence for choosing Mounjaro. For patients where cost is important, the health economics calculation is more complex — Wegovy’s lower cost partially offsets the weight loss difference for many patients.

Ozempic in the Media: Why the Name Is Misleading

The persistence of “Ozempic” as the generic cultural term for GLP-1 weight loss medications has created a specific communication problem in UK clinical practice. Patients arrive at Slinic asking for “Ozempic” when they mean any of: Wegovy, Mounjaro, or semaglutide generally. Here is the correct clinical translation:

Summary: 5 Things Every Patient Should Know

1. Ozempic is not licensed for weight loss in the UK — Wegovy is the correct semaglutide product for weight management. They contain the same drug at different doses.
2. The right comparison is Wegovy vs Mounjaro — both NICE-approved and MHRA-licensed for weight management. SURMOUNT-5 showed Mounjaro produces 6.5 percentage points more weight loss on average.
3. Wegovy is cheaper — approximately £75/month less expensive than Mounjaro at maintenance doses at Slinic. Both are extraordinary by historical weight loss medication standards.
4. Wegovy has the cardiovascular benefit label — the NICE April 2026 cardiovascular indication (BMI 27+ with established CVD) applies to semaglutide (Wegovy), not tirzepatide (Mounjaro).
5. Wegovy now has an oral option — the Wegovy pill (MHRA June 2026) removes the injection requirement for patients who prefer an oral medication. No equivalent oral Mounjaro exists yet.

Ozempic Supply Issues: Why It Matters for Weight Loss Patients

One of the reasons Slinic specifically does not prescribe Ozempic off-label for weight loss is the supply issue. Ozempic is a medically necessary medication for hundreds of thousands of UK adults with type 2 diabetes. When Ozempic is prescribed off-label for weight loss at scale, it creates supply shortages for T2D patients who have no alternative.

NHS England and NHS Scotland both issued guidance in 2023–2024 specifically asking prescribers not to initiate Ozempic for new patients with obesity and to restrict it to T2D patients who already depend on it. This guidance reflects the clinical reality: with Wegovy and Mounjaro both available in licensed weight management formulations, prescribing Ozempic off-label for weight loss serves no clinical purpose while creating real harm for T2D patients.

Slinic’s policy — never prescribing Ozempic off-label when licensed alternatives are available — is aligned with NHS guidance, MHRA intent, and clinical ethics. When patients say “I want Ozempic,” we explain this distinction and prescribe the correct licensed product for their needs.

The Future: Will Ozempic Ever Be Licensed for Weight Loss?

The short answer is no — not as Ozempic. The weight management-licensed version of semaglutide IS Wegovy, at higher doses with the weight management indication. Novo Nordisk has structured their portfolio to keep the diabetes indication (Ozempic) and weight management indication (Wegovy) as separate products with separate licences, even though the drug is identical.

What may change is the oral format: Rybelsus is the licensed oral semaglutide for T2D (14mg daily). The Wegovy pill (25mg daily, MHRA approved June 2026) is the licensed oral semaglutide for weight management. The pattern continues: same drug, different product, different licence, different dose.

There is also no prospect of a lower-cost generic semaglutide in the near term — Novo Nordisk holds the patent for semaglutide in the UK for a number of years, meaning the Wegovy brand product at Slinic is the only legitimate licensed option. Compounded semaglutide, overseas semaglutide, and unbranded “semaglutide” injections sold online are not legitimate alternatives — they carry the same risks as counterfeit Mounjaro.

How to Start the Right Medication at Slinic

Whether your goal is maximum weight loss (Mounjaro), lower cost (Wegovy), cardiovascular protection (Wegovy), or avoiding injections (Wegovy pill — coming soon), Slinic has the right licensed medication for you. Here is how to start:

1. Complete the free eligibility assessment at slinic.co.uk — 2 minutes, no obligation
2. Disclose your medical history — conditions, medications, BMI — accurately and completely
3. A registered Slinic prescriber reviews your assessment — typically within a few hours
4. If approved, your medication is dispatched within 24 hours by cold-chain tracked delivery
5. Monthly check-ins are scheduled from the start — dose management, side effect review, progress monitoring

If you are unsure whether Mounjaro or Wegovy is better for your specific situation, your Slinic prescriber will discuss both options with you at your assessment. There is no pressure to choose one over the other — the right medication depends on your clinical circumstances, cost constraints, and personal preferences.

Frequently Asked Questions